Literature DB >> 28195930

Treatment Duration With Long-Acting Injectable Antipsychotics After In-hospital Initiation: A Retrospective Cohort Study.

Hans Rittmannsberger1, Jan Rosenleitner, Gertraud Malsiner-Walli, Regina Werl, Barbara Rittmannsberger, Kurosch Yazdi.   

Abstract

PURPOSE: Long-acting injectable (LAI) antipsychotics are recommended especially for patients with multiple admissions and poor adherence. The empirical basis of this strategy is a matter of debate.
METHODS: In a retrospective cohort study extending over 6 years, all patients admitted for inpatient treatment with a diagnosis of psychotic disorders according to International Statistical Classification of Diseases and Related Health Problems, 10th Revision (F2) were screened for treatment episodes with a new start of an LAI. Indication for LAI treatment was based primarily on previous medication default. All-cause discontinuation was used as a measure of treatment efficiency. Patients with early dropout (termination of LAI treatment within 6 months) were compared with patients with longer treatment (treatment >6 months) for sociodemographic and treatment variables using bivariate and multivariate analyses.
RESULTS: A total of 194 treatment episodes with new start of LAIs were identified. Almost one half dropped out within 6 months (early dropout: n = 95 [49%]; mean duration, 2.2 months). Termination of treatment was mainly due to patients' refusal to continue. However, almost a third of patients (61; 31.4%) had a treatment duration of more than 2 years. In a multivariate Cox regression model, longer treatment duration was associated with older age (P = 0.05), not being single (P = 0.04), fewer admissions during the year preceding the index episode (P = 0.02), and better ratings for adherence at the index episode (P = 0.03).
CONCLUSIONS: There are both more patients than expected leaving the treatment early and more patients than expected staying for long periods, even among patients with a history of poor adherence.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28195930     DOI: 10.1097/JCP.0000000000000672

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  3 in total

1.  Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres.

Authors:  Lorenzo Berardi; Ippazio Cosimo Antonazzo; Carlo Piccinni; Emanuel Raschi; Emanuele Forcesi; Angelo Fioritti; Domenico Berardi; Fabrizio De Ponti; Antonella Piazza; Elisabetta Poluzzi
Journal:  PLoS One       Date:  2019-02-15       Impact factor: 3.240

2.  Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study.

Authors:  Kyle A McKee; Candice E Crocker; Philip G Tibbo
Journal:  BMC Psychiatry       Date:  2021-12-20       Impact factor: 3.630

3.  Comparing Long-Acting Antipsychotic Discontinuation Rates Under Ordinary Clinical Circumstances: A Survival Analysis from an Observational, Pragmatic Study.

Authors:  Federico Bertolini; Giovanni Ostuzzi; Michela Pievani; Andrea Aguglia; Francesco Bartoli; Paola Bortolaso; Camilla Callegari; Mariarita Caroleo; Giuseppe Carrà; Mariangela Corbo; Armando D'Agostino; Pasquale De Fazio; Fabio Magliocco; Giovanni Martinotti; Edoardo Giuseppe Ostinelli; Marco Piero Piccinelli; Federico Tedeschi; Corrado Barbui
Journal:  CNS Drugs       Date:  2021-03-29       Impact factor: 5.749

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.